Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis.
Buckle G, Bandari D, Greenstein J, Gudesblatt M, Khatri B, Kita M, Repovic P, Riser E, Weinstock-Guttman B, Thrower B, Loring S, Riester K, Everage N, Prada C, Koulinska I, Mann M. Buckle G, et al. Among authors: koulinska i. Mult Scler J Exp Transl Clin. 2020 Apr 29;6(2):2055217320918619. doi: 10.1177/2055217320918619. eCollection 2020 Apr-Jun. Mult Scler J Exp Transl Clin. 2020. PMID: 32440353 Free PMC article.
Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND.
Repovic P, Robertson D, Kresa-Reahl K, Cohan SL, Su R, Avila R, Koulinska I, Mendoza JP. Repovic P, et al. Among authors: koulinska i. Neurol Ther. 2021 Jun;10(1):169-182. doi: 10.1007/s40120-020-00223-2. Epub 2020 Nov 23. Neurol Ther. 2021. PMID: 33225410 Free PMC article.
Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics.
Hersh CM, Altincatal A, Belviso N, Kapadia S, de Moor C, Rudick R, Williams JR, Miller C, Koulinska I. Hersh CM, et al. Among authors: koulinska i. Mult Scler J Exp Transl Clin. 2022 Jan 7;8(1):20552173211069852. doi: 10.1177/20552173211069852. eCollection 2022 Jan-Mar. Mult Scler J Exp Transl Clin. 2022. PMID: 35024161 Free PMC article.
Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS.
Hersh CM, Kieseier B, de Moor C, Miller DM, Campagnolo D, Williams JR, Fitzgerald KC, Xiong K, McGinley MP, Hyland M, Rudick RA, Ziemssen T, Koulinska I. Hersh CM, et al. Among authors: koulinska i. Mult Scler J Exp Transl Clin. 2021 Apr 15;7(2):20552173211004634. doi: 10.1177/20552173211004634. eCollection 2021 Apr-Jun. Mult Scler J Exp Transl Clin. 2021. PMID: 33948221 Free PMC article.
Measuring treatment response to advance precision medicine for multiple sclerosis.
Calabresi PA, Kappos L, Giovannoni G, Plavina T, Koulinska I, Edwards MR, Kieseier B, de Moor C, Sotirchos ES, Fisher E, Rudick RA, Sandrock A. Calabresi PA, et al. Among authors: koulinska i. Ann Clin Transl Neurol. 2021 Nov;8(11):2166-2173. doi: 10.1002/acn3.51471. Epub 2021 Oct 26. Ann Clin Transl Neurol. 2021. PMID: 34704393 Free PMC article. Clinical Trial.
Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes.
Min J, Cohan S, Alvarez E, Sloane J, Phillips JT, van der Walt A, Koulinska I, Fang F, Miller C, Chan A. Min J, et al. Among authors: koulinska i. Neurol Ther. 2019 Jun;8(1):109-119. doi: 10.1007/s40120-019-0127-2. Epub 2019 Jan 31. Neurol Ther. 2019. PMID: 30706431 Free PMC article.
22 results